Opthea Ltd
ASX:OPT
Intrinsic Value
Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. [ Read More ]
The intrinsic value of one OPT stock under the Base Case scenario is 0.01 AUD. Compared to the current market price of 0.645 AUD, Opthea Ltd is Overvalued by 98%.
Valuation Backtest
Opthea Ltd
Run backtest to discover the historical profit from buying and selling OPT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Opthea Ltd
Current Assets | 166.3m |
Cash & Short-Term Investments | 157.1m |
Receivables | 5.8m |
Other Current Assets | 3.5m |
Non-Current Assets | 165.2k |
PP&E | 154.6k |
Other Non-Current Assets | 10.6k |
Current Liabilities | 32.6m |
Accounts Payable | 31.7m |
Other Current Liabilities | 886.2k |
Non-Current Liabilities | 180.8m |
Long-Term Debt | 180.8m |
Other Non-Current Liabilities | 10.2k |
Earnings Waterfall
Opthea Ltd
Revenue
|
117.1k
USD
|
Cost of Revenue
|
-233.9k
USD
|
Gross Profit
|
-116.8k
USD
|
Operating Expenses
|
-165.1m
USD
|
Operating Income
|
-165.2m
USD
|
Other Expenses
|
3.6m
USD
|
Net Income
|
-161.6m
USD
|
Free Cash Flow Analysis
Opthea Ltd
What is Free Cash Flow?
OPT Profitability Score
Profitability Due Diligence
Opthea Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Opthea Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
OPT Solvency Score
Solvency Due Diligence
Opthea Ltd's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Opthea Ltd's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OPT Price Targets Summary
Opthea Ltd
Shareholder Return
OPT Price
Opthea Ltd
Average Annual Return | 54.31% |
Standard Deviation of Annual Returns | 173.25% |
Max Drawdown | -92% |
Market Capitalization | 427.5m AUD |
Shares Outstanding | 662 809 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing and commercializing therapies primarily for eye diseases. The firm's lead product candidate OPT-302, is a soluble form of vascular endothelial growth factors-3 (VEGFR 3) in clinical development as a therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The firm's technology platform focuses on vascular endothelial growth factors, such as VEGF C, VEGF D and VEGF Receptor 3 for the treatment of diseases associated with blood and lymphatic vessel growth (angiogenesis and lymphangiogenesis), as well as vascular leakage. The company has also conducted various activities to support its clinical development programs in wet AMD and DME, including clinical data analysis and manufacturing of OPT-302 for use in Phase III clinical trials.
Contact
IPO
Employees
Officers
The intrinsic value of one OPT stock under the Base Case scenario is 0.01 AUD.
Compared to the current market price of 0.645 AUD, Opthea Ltd is Overvalued by 98%.